Skip to main content

Table 1

From: Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

 

Median OS, mo (95% CI)

OS rate, % (95% CI)

  

1-yr

2-yr

Treatment group

   

 0.3 mg/kg (n=22)

16.4 (10.1-NR)

71 (47-86)

44 (22-64)

 2.0 mg/kg (n=22)

NR

72 (48-86)

61 (36-78)

 10 mg/kg (n=23)

25.2 (12.0-NR)

74 (48-88)

51 (27-71)

 10 mg/kg (naïve) (n=24)

NR

81 (57-92)

76 (51-89)

PD-L1 expression

   

 ≥5% (n=18)

NR

71 (44-87)

64 (37-82)

<5% mg/kg (n=38)

23.4 (13.1-33.3)

71 (52-83)

48 (30-64)

  1. NR = not reached